SAN FRANCISCO — In a meeting with Dermira (DERM) Tuesday, CEO Tom Wiggans and his management team said they’re on track to report results this quarter from twin Phase 3 clinical trials of its novel, acne-clearing drug DRM01. It’s a pivotal moment for the small biotech company, targeting a very common skin disease with the only topical drug designed to shut down the production of sebum, the oily, waxy matter excreted by tiny glands in the skin.

There are no certainties in biotech, but I’ll stick my neck out and predict Dermira wins with DRM01. In its Phase 2 study, the drug showed a significant and consistent ability to reduce by half the number of inflammatory and non-inflammatory lesions compared to a vehicle control. Study investigators also assessed DRM01 patients and found a significant doubling of the improvement in their overall acne severity score compared to control. The drug’s safety profile was clean.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I would note that the Phase IIb results (last reported for this drug) reflected the endpoint of “at least a two-point improvement from baseline on the five-point Investigator’s Global Assessment (IGA) scale”. This is not as rigorous as other drugs in the space, which add a stipulation of achieving IGA score of 0-1. Consider Sol-Gel Technologies, which more recently reported data under this more stringent endpoint.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy